Cover Image
市場調查報告書

運動障礙 : 開發中產品分析

Dyskinesia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 192566
出版日期 內容資訊 英文 147 Pages
訂單完成後即時交付
價格
Back to Top
運動障礙 : 開發中產品分析 Dyskinesia - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 147 Pages
簡介

所謂運動障礙,是指肌肉的不自主運動,或是難以自行控制肌肉運動的狀態。主要的症狀,有面部扭曲,手指隨意動作,下巴搖擺,反複咬,舌頭伸出等。健康生活方式和藥物療法可抑制病情。

本報告提供全球各國的運動障礙(異動症)治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

運動障礙(異動症)概要

治療藥的開發

  • 運動障礙的開發中產品:概要
  • 各企業的開發平台
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑

運動障礙開發治療藥的企業

  • Adamas Pharmaceuticals Inc
  • Addex Therapeutics Ltd
  • Advicenne SA
  • Astraea Therapeutics LLC
  • Avanir Pharmaceuticals Inc
  • Bionomics Ltd
  • Catalyst Biosciences Inc
  • Catalyst Pharmaceuticals Inc
  • Cavion LLC
  • Clevexel Pharma SAS
  • EpiVax Inc
  • Heptares Therapeutics Ltd
  • Ipsen SA
  • Merz Pharma GmbH & Co KgaA
  • Neurim Pharmaceuticals Ltd
  • Neurocrine Biosciences Inc
  • Neurolixis Inc
  • Osmotica Pharmaceutical Corp
  • Phenomenome Discoveries Inc
  • Sage Therapeutics Inc
  • SciFluor Life Sciences LLC
  • SOM Biotech SL
  • Synchroneuron Inc
  • Teva Pharmaceutical Industries Ltd

藥物簡介

運動障礙治療藥:開發暫停的產品

運動障礙治療藥:開發中止的產品

運動障礙相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9708IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H2 2017, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 4, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dyskinesia - Overview
    • Dyskinesia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Dyskinesia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Dyskinesia - Companies Involved in Therapeutics Development
    • Adamas Pharmaceuticals Inc
    • Addex Therapeutics Ltd
    • Advicenne SA
    • Avanir Pharmaceuticals Inc
    • Bionomics Ltd
    • Catalyst Biosciences Inc
    • Cavion LLC
    • Clevexel Pharma SAS
    • EpiVax Inc
    • Heptares Therapeutics Ltd
    • Ipsen SA
    • Merz Pharma GmbH & Co KgaA
    • Neurim Pharmaceuticals Ltd
    • Neurocrine Biosciences Inc
    • Neurolixis Inc
    • Osmotica Pharmaceutical Corp
    • Phenomenome Discoveries Inc
    • Sage Therapeutics Inc
    • SciFluor Life Sciences LLC
    • SOM Biotech SL
    • Synchroneuron Inc
  • Dyskinesia - Drug Profiles
    • (dextromethorphan + quinidine sulfate) - Drug Profile
    • A-2M13677 - Drug Profile
    • abobotulinumtoxinA - Drug Profile
    • acamprosate calcium SR - Drug Profile
    • amantadine hydrochloride ER - Drug Profile
    • amantadine hydrochloride ER - Drug Profile
    • AT-127 - Drug Profile
    • AT-326 - Drug Profile
    • AT-403 - Drug Profile
    • befiradol - Drug Profile
    • brexanolone - Drug Profile
    • CVXL-0107 - Drug Profile
    • CX-8998 - Drug Profile
    • cycloserine - Drug Profile
    • dipraglurant IR - Drug Profile
    • Drug for Dyskinesia - Drug Profile
    • Drug for Tardive Dyskinesia - Drug Profile
    • Drugs for Dyskinesia - Drug Profile
    • Gene Therapy to Inhibit TRH for Dyskinesia - Drug Profile
    • HTL-14242 - Drug Profile
    • incobotulinumtoxin A - Drug Profile
    • IRL-790 - Drug Profile
    • JM-010 - Drug Profile
    • MLR-1019 - Drug Profile
    • NBI-640756 - Drug Profile
    • Neu-120 - Drug Profile
    • Neu-240 - Drug Profile
    • onabotulinumtoxinA - Drug Profile
    • PCT-3010 - Drug Profile
    • PPI-1011 - Drug Profile
    • RNAi Gene Therapy to Inhibit NURR1 for Dyskinesia - Drug Profile
    • SAGE-217 - Drug Profile
    • SK-609 - Drug Profile
    • Small Molecule for Dyskinesia - Drug Profile
    • Small Molecule for Dyskinesia - Drug Profile
    • Small Molecules for Neurodegenerative Disease - Drug Profile
    • Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile
    • Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile
    • Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
    • Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile
    • Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile
    • SOM-3355 - Drug Profile
    • TC-8831 - Drug Profile
    • tetrabenazine - Drug Profile
    • valbenazine tosylate - Drug Profile
  • Dyskinesia - Dormant Projects
  • Dyskinesia - Discontinued Products
  • Dyskinesia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Dyskinesia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Dyskinesia - Pipeline by Adamas Pharmaceuticals Inc, H2 2017
  • Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2017
  • Dyskinesia - Pipeline by Advicenne SA, H2 2017
  • Dyskinesia - Pipeline by Avanir Pharmaceuticals Inc, H2 2017
  • Dyskinesia - Pipeline by Bionomics Ltd, H2 2017
  • Dyskinesia - Pipeline by Catalyst Biosciences Inc, H2 2017
  • Dyskinesia - Pipeline by Cavion LLC, H2 2017
  • Dyskinesia - Pipeline by Clevexel Pharma SAS, H2 2017
  • Dyskinesia - Pipeline by EpiVax Inc, H2 2017
  • Dyskinesia - Pipeline by Heptares Therapeutics Ltd, H2 2017
  • Dyskinesia - Pipeline by Ipsen SA, H2 2017
  • Dyskinesia - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017
  • Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
  • Dyskinesia - Pipeline by Neurocrine Biosciences Inc, H2 2017
  • Dyskinesia - Pipeline by Neurolixis Inc, H2 2017
  • Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp, H2 2017
  • Dyskinesia - Pipeline by Phenomenome Discoveries Inc, H2 2017
  • Dyskinesia - Pipeline by Sage Therapeutics Inc, H2 2017
  • Dyskinesia - Pipeline by SciFluor Life Sciences LLC, H2 2017
  • Dyskinesia - Pipeline by SOM Biotech SL, H2 2017
  • Dyskinesia - Pipeline by Synchroneuron Inc, H2 2017
  • Dyskinesia - Dormant Projects, H2 2017
  • Dyskinesia - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Dyskinesia - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Dyskinesia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top